SG/PUT/ASTRAZENECA/7000/0.1/21.03.25 | Market Closed - Börse Stuttgart 02:14:07 2024-07-16 am EDT | ||
| 0.016 EUR | -42.86% |
|
| Current month | -11.11% | ||
| 1 month | -27.27% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 0.016 | -42.86% |
| 24-07-15 | 0.028 | +3.70% |
| 24-07-12 | 0.027 | +68.75% |
| 24-07-11 | 0.016 | -20.00% |
| 24-07-10 | 0.02 | +11.11% |
Delayed Quote Börse Stuttgart
Last update July 16, 2024 at 02:14 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SU7960 |
| ISIN | DE000SU79605 |
| Date issued | 2024-02-13 |
| Strike | 7,000 p |
| Maturity | 2025-03-21 (248 Days) |
| Parity | 10 : 1 |
| Emission price | 0.21 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.2 € |
|---|---|
| Lowest since issue | 0.015 € |
| Spread | 0.029 € |
| Spread % | 61.70% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
156.8
USD
Average target price
177.6
USD
Spread / Average Target
+13.29%
- Stock Market
- Warrants
- Warrant
